Replimune Group, Inc. (NASDAQ:REPL) Holdings Boosted by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 25.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 128,208 shares of the company’s stock after purchasing an additional 25,939 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.19% of Replimune Group worth $1,405,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in REPL. Nisa Investment Advisors LLC grew its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. Point72 DIFC Ltd acquired a new position in shares of Replimune Group during the second quarter valued at $57,000. Arizona State Retirement System bought a new position in shares of Replimune Group during the second quarter worth about $108,000. Quest Partners LLC increased its holdings in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after acquiring an additional 3,150 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in Replimune Group in the 1st quarter valued at about $140,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. BMO Capital Markets increased their price target on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Finally, Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Stock Up 8.4 %

Shares of REPL stock opened at $14.38 on Wednesday. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business’s fifty day moving average is $11.64 and its 200-day moving average is $9.81. The stock has a market cap of $983.88 million, a PE ratio of -4.37 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Equities analysts expect that Replimune Group, Inc. will post -3.02 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.